Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations
Abstract
Antimicrobial resistance poses a major challenge in the treatment of Acinetobacter baumannii. Acinetobacter spp. are intrinsically resistant to a number of commonly used antibiotics. Over the past 3 years, the European and American Professional Societies have provided important guidelines on the treatment options for carbapenem-resistant A. baumannii (CRAB). Here, we review the recent literature on combination regimens for CRAB as well as carbapenem-susceptible A. baumannii infections. We discuss the strengths and weaknesses of various agents used in combination, depending on the site of infection and their pharmacokinetic properties. Consistent with the 2024 Infectious Diseases of America (IDSA) update, sulbactam-durlobactam, in combination with background carbapenem therapy, remains the combination with the greatest reduction in mortality for pulmonary infections and has promising outcomes in bloodstream infections with CRAB. Sulbactam-based combination therapy remains an ideal part of targeted strategies and has been shown to be associated with reduced mortality. Certain agents have been highlighted in the literature for suboptimal outcomes, primarily pulmonary infections treated with cefiderocol, tigecycline, and eravacycline. Studies including non-pulmonary infections, specifically bacteremia and central nervous system (CNS) infections, are overall limited to case series and subgroup analyses. Important areas for further research include breakpoint evaluations for…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.